(Press-News.org) Among patients with diabetic kidney disease and hyperkalemia (elevated potassium levels in the blood), a potentially life-threatening condition, those who received the new drug patiromer, twice daily for four weeks, had significant decreases in potassium levels which lasted through one year, according to a study in the July 14 issue of JAMA.
Patients at the highest risk for hyperkalemia are those taking renin-angiotensin-aldosterone system (RAAS) inhibitors with stage 3 or greater chronic kidney disease (CKD) who also have diabetes mellitus, heart failure, or both. Because of the limited utility of current options to manage hyperkalemia, particularly over the long term, clinicians frequently must either avoid using RAAS inhibitors or use them at lower than recommended doses, according to background information in the article. Use of RAAS can help further slow progression of renal disease among patients with diabetes.
Patiromer is an orally administered drug being investigated for the treatment of hyperkalemia. The active portion, patiromer, is a non-absorbed polymer that binds potassium throughout the gastrointestinal tract, thus increasing excretion of potassium in the stool and lowering serum potassium levels. Prior patiromer clinical trials have demonstrated the drug's utility in treating hyperkalemia in other at-risk populations for periods ranging from a few days to up to 12 weeks.
George L. Bakris, M.D., of University of Chicago Medicine, Chicago, and colleagues randomly assigned 306 outpatients with type 2 diabetes and an elevated serum potassium level to 1 of 3 starting doses of patiromer twice daily. All patients received RAAS inhibitors prior to and during study treatment. The phase 2 trial was conducted at 48 sites in Europe from June 2011 to June 2013.
The researchers found that patiromer significantly reduced serum potassium levels across dose groups (8.4 - 33.6 g/d) through week 4 in patients with a varying severity of hyperkalemia, and consistently maintained normal serum potassium levels over 52 weeks. Over this period, patiromer use demonstrated high adherence, low risk of hypokalemia (abnormally low level of potassium in the blood), and minimal discontinuations because of adverse events.
Over the 52 weeks, hypomagnesemia (abnormally low level of magnesium in the blood; 7 percent) was the most common treatment-related adverse event, mild to moderate constipation (6 percent) was the most common gastrointestinal adverse event, and hypokalemia occurred in 6 percent of patients.
The authors note that based on the findings of this study, a phase 3 study was performed in which patiromer demonstrated consistent efficacy as shown in this study. "The consistency of results across the secondary end points [including average change in serum potassium level through 52 weeks] supports the conclusions regarding long-term efficacy."
(doi:10.1001/jama.2015.7446; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: This study was sponsored and funded by Relypsa. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
Editorial: Treatment of Hyperkalemia
In an accompanying editorial, Wolfgang C. Winkelmayer, M.D., Sc.D., of the Baylor College of Medicine, Houston, and Associate Editor, JAMA, comments on the findings of this study.
"Once hyperkalemia drugs are approved based on trials of the surrogate of potassium concentration, it is uncertain if the manufacturers will be motivated to conduct such crucial trials of the hard end points that patients care about (reduced progression of CKD and deferral of dialysis; better heart failure outcomes), especially if the alternative is to spend the same dollars on marketing and company-sponsored and -directed contract research of their already-approved product. Thus, as part of the approval process, the FDA and other agencies should consider mandating a sizeable postmarketing trial and safety surveillance program to clearly establish whether the assumptions underlying the value proposition of chronic hyperkalemia treatments actually hold."
(doi:10.1001/jama.2015.7521; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.
INFORMATION:
An examination of state vaccination requirements for adolescents finds that the human papillomavirus (HPV) vaccine is currently required in only two states, many fewer than another vaccine associated with sexual transmission (hepatitis B) and another primarily recommended for adolescents (meningococcal conjugate), according to a study in the July 14 issue of JAMA.
Eight years after HPV vaccines were first recommended in the United States, vaccination coverage is substantially below the Healthy People 2020 target of 80 percent. Data from the U.S. Centers for Disease Control ...
Berkeley -- Researchers at the University of California, Berkeley, in collaboration with scientists at the Gladstone Institutes, have developed a template for growing beating cardiac tissue from stem cells, creating a system that could serve as a model for early heart development and a drug-screening tool to make pregnancies safer.
In experiments to be published Tuesday, July 14, in the journal Nature Communications, the researchers used biochemical and biophysical cues to prompt stem cells to differentiate and self-organize into micron-scale cardiac tissue, including ...
Boston, MA - A new study from Harvard T.H. Chan School of Public Health researchers has found that it would be cost-effective to treat 48-67% of all adults aged 40-75 in the U.S. with cholesterol-lowering statins. By expanding the current recommended treatment guidelines and boosting the percentage of adults taking statins, an additional 161,560 cardiovascular-related events could be averted, according to the researchers.
"The new cholesterol treatment guidelines have been controversial, so our goal for this study was to use the best available evidence to quantify the ...
WASHINGTON, DC --July 14, 2015--Multiple species of bacteria working together in healthy guts are responsible for keeping out nasty bacterial invader, Clostridium difficile, a hospital-acquired culprit responsible for 15,000 deaths each year. The study, published this week in mBio, the online open-access journal of the American Society for Microbiology, could lead to tests to predict which hospital patients are at highest risk of infection and better management of infections.
"Hospital-acquired C. difficile infections have bloomed as a problem in the last 10-15 years, ...
High-fat feeding can cause impairments in the functioning of the mesolimbic dopamine system, says Stephanie Fulton of the University of Montreal and the CHUM Research Centre (CRCHUM.) This system is a critical brain pathway controlling motivation. Fulton's findings, published today in Neuropsychopharmacology, may have great health implications. "Our research shows that independent of weight gain and obesity, high-fat feeding can cause impairments in the functioning of the brain circuitry profoundly implicated in mood disorders, drug addiction, and overeating - several states ...
Despite modern chemoradiation therapy it is still very difficult to give reliable prognoses for malignant gliomas. Surgical removal of the glioma is still the preferred method of treatment. Doctors at Universitätsklinikum Erlangen's Department of Neurosurgery have now developed a new procedure for analysing radiological imaging scans which makes it possible to predict the course of a disease relatively precisely. Their findings have now been published in the journal 'Scientific Reports'.*
The Friedlein Grading A/B (FGA/B) classification system - named after the physician ...
HOUSTON - (July 14, 2015) - After Amazon announced plans last week for a day of online retail discounts July 15 comparable to Black Friday, Wal-Mart is launching a rival sale online the same day. Who will win the e-commerce battle? Winning is a matter of consistent superior e-service quality -- not just on one particular day of the year, according to new research from Rice University's Jones Graduate School of Business.
"Increased e-service quality is associated with increased customer satisfaction, which then leads to higher repurchase intentions," said Vikas Mittal, ...
Putnam Valley, NY. (July 14, 2015) - Systemic lupus erythematosus (SLE) is an autoimmune disease that produces autoantibodies and subsequent immune reactions that can lead to a variety of symptoms, including inflammation of the kidneys, or nephritis. When researchers transplanted mesenchymal stem cells (MSCs) derived from human bone marrow into mice modeled with SLE, they found that inflammation was reduced and nephritis "attenuated." They suggested that their study revealed a "novel mechanism" by which the MSCs can regulate the progression of autoimmune diseases such as ...
HOUSTON - (July 14, 2015) - From 2004 to 2010 in Texas, mental illness was the most common reason for the hospitalization of children ages 10-14 while pregnancy/birth was the most common reason for the hospitalization of adolescents ages 15-17, according to researchers at The University of Texas Health Science Center at Houston (UTHealth) Medical School.
The results were published in the July issue of Hospital Pediatrics, a journal of the American Academy of Pediatrics.
"We were surprised by those two findings and the related costs in millions of dollars," said Bethanie ...
WEST LAFAYETTE, Ind. - New research is revealing details about how the exoskeleton of a certain type of deep-sea shrimp allows the animal to survive scalding hot waters in hydrothermal vents thousands of feet under water.
"A biological species surviving in that kind of extreme environment is a big deal," said Vikas Tomar, an associate professor in Purdue University's School of Aeronautics and Astronautics. "And shrimp are a great test case for evolution because you can find different species all over the world living at various depths and with a range of adaptation requirements."
He ...
